Sensei Biotherapeutics (HAM:407) Total Liabilities : €7.56 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics Total Liabilities?

Sensei Biotherapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was €7.56 Mil.

Sensei Biotherapeutics's quarterly Total Liabilities declined from Sep. 2023 (€9.99 Mil) to Dec. 2023 (€8.69 Mil) and declined from Dec. 2023 (€8.69 Mil) to Mar. 2024 (€7.56 Mil).

Sensei Biotherapeutics's annual Total Liabilities increased from Dec. 2021 (€5.94 Mil) to Dec. 2022 (€14.13 Mil) but then declined from Dec. 2022 (€14.13 Mil) to Dec. 2023 (€8.69 Mil).

Sensei Biotherapeutics Total Liabilities Historical Data

The historical data trend for Sensei Biotherapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensei Biotherapeutics Total Liabilities Chart

Sensei Biotherapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

62.89

64.01

5.94

14.13

8.69

Sensei Biotherapeutics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															12.22	9.58	9.99	8.69	7.56

Sensei Biotherapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sensei Biotherapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.175	+	(3.456	+	0.061
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	8.69

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	68.201	-	59.509
	=	8.69

Sensei Biotherapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4.593	+	(2.908	+	0.062
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	7.56

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	61.359	-	53.796
	=	7.56

Sensei Biotherapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Sensei Biotherapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sensei Biotherapeutics (HAM:407) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (HAM:407) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

SNSE:USA 407:Germany

Address

1405 Research Boulevard, Suite 710, Boston, MA, USA, 02210

Website

https://www.senseibio.com

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. The company currently has three investigational products. 1) SNS-101 is a conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell activation): 2) SNS-102 is a conditionally active monoclonal antibody targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), an immune checkpoint often expressed on macrophages: 3) SNS-103 is a conditionally active monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1), also known as CD39.

Sensei Biotherapeutics (HAM:407) Headlines

No Headlines